Investigation of serum survivin in dogs suffering from cancer: a multicenter study
- Author:
Annkathrin ESTALLER
1
;
Martin KESSLER
;
Axel WEHREND
;
Frank GESSLER
;
Johannes HIRSCHBERGER
;
Stephan NEUMANN
Author Information
- Publication Type:Original Article
- From:Journal of Veterinary Science 2021;22(6):e79-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:In contrast to human medicine, only a small number of serum tumor markers are established in veterinary medicine even though they are a non-invasive diagnostic tool.
Objectives:This study examined whether survivin could be suitable as a potential canine serum tumor marker.
Methods:This study measured the serum survivin concentrations of dogs with mammary tumors (n = 33), squamous cell carcinoma (n = 9), soft-tissue sarcoma (n = 18) and multicentric lymphoma (n = 22), using a commercially available, competitive immunoassay kit (BlueGene). The serum survivin concentrations were compared with those of a healthy control group (n = 20) and a control group of dogs with non-neoplastic diseases (n = 17).
Results:Dogs with malignant tumors had serum survivin concentrations between 15 and 5,906 pg/mL (median, 72 pg/mL), those in the healthy group ranged from 7 to 99 pg/mL (median, 21 pg/mL) and those in the group of dogs suffering from non-neoplastic diseases from 15 to 93 pg/mL (median, 42 pg/mL). The differences in the survivin concentrations between the healthy dogs and dogs with malignant tumors and between the dogs with nonneoplastic diseases and those with malignant tumors were significant (p < 0.001 and p = 0.006, respectively).
Conclusions:The serum survivin concentrations in dogs with malignant tumors, with some exceptions, are higher than in dogs with benign tumors and dogs that do not suffer from a malignancy. Therefore, survivin can provide information on the presence of malignant tumors and be used as a tumor marker in dogs.
